Last updated 2026-07-20
Portfolio
0
in our dataset
Rounds participated
0
Rounds led
0
Rounds' value
—
total disclosed, rounds participated
Stages
—
About
Prof. John Finberg is a professor of pharmacology at the Faculty of Medicine, Technion - Israel Institute of Technology in Haifa, Israel. He is recognized for his instrumental role, alongside Prof. Moussa Youdim, in the early clinical development of rasagiline, an anti-Parkinson's drug marketed globally as AZILECT. Finberg's research focuses on neuropharmacology and neurodegenerative diseases. He is also an investor in KidneyCure Ltd., an Israeli biotech startup developing cell-therapy technology for chronic kidney disease.
Portfolio
No portfolio companies in this dataset yet.
Q&A
- What is Prof. John Finberg's primary investment focus?
- Prof. John Finberg is an angel investor based in Israel.
- What is the typical investment stage for Prof. John Finberg?
- Prof. John Finberg's investment stages are not disclosed in the provided data.
- What is Prof. John Finberg's preferred check size?
- Prof. John Finberg's check size is undisclosed.
- Does Prof. John Finberg have a specific geographic focus for investments?
- Prof. John Finberg is based in Israel, but preferred geographies for investment are not specified.
- What is Prof. John Finberg's investment thesis?
- Prof. John Finberg's investment thesis is not disclosed.
- When was Prof. John Finberg established as an investor?
- Prof. John Finberg was created in startupim data on May 11, 2019.